Intensity Therapeutics, Inc. (INTS)
INTSNASDAQ-CMBiotechnology: Biological Products (No Diagnostic Substances)
$3.09
-0.0300 (-0.96%) today
Closed, Nov 10, 4:00 PM ET
- Market cap
- $10.20m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $2.80 to $15.00
- Average volume
- 17.9k
- Previous close
- $3.12
Analysts
2 coveringBuy2 buy, 0 hold, 0 sell
Targets a year out average $11.00, +256.0% from here
Earnings
next estimate $-1.13Next report
Mar 2026
+28.9%
Jun 2026
-37.0%
Sep 2026
-16.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$2.73m | -$3.14m | -$2.53m | -$3.08m |
| Net income | -$2.67m | -$3.05m | -$2.43m | -$3.01m |
News
8 latest- Intensity Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateFintel · 5 days ago
- Intensity (INTS) Q3 2026 Earnings Call TranscriptThe Motley Fool · 5 days ago
- Intensity Therapeutics, Inc Loss At -$3.544 Mln In Q3 RTTNews · 6 days ago
- Intensity's Q2 Loss Widens Marginally As Trials For Breast Cancer Drug Resume RTTNews · Sep 4, 2026
- Intensity Therapeutics (INTS) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 11, 2026
- Cue Biopharma Appoints Ahlers As CFO Following IND Filing And Pipeline Progress RTTNews · Aug 4, 2026
- Intensity Resumes Phase 2 INVINCIBLE-4 Study For INT230-6 In Breast Cancer With Lower Dose RTTNews · Jul 17, 2026
- Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's WhyZacks · May 27, 2026
The company
Intensity is a late-stage clinical biotechnology company whose novel engineered chemistry enables aqueous cytotoxic-containing drug formulations to mix and saturate a tumor's dense, high-fat, pressurized environment following direct intratumoral injection. As a result of the saturation, Intensity's clinical trials have demonstrated the ability of INT230-6 to kill tumors and elicit an adaptive immune response within days of injection, representing a new approach to cancer cell death that holds the potential to shift the treatment paradigm and turn many deadly cancers into chronic diseases, even for malignancies that do not respond to conventional immunotherapy.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- intensitytherapeutics.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.